WO2006062481A1 - Nouveaux derives de benzofurane et leur utilisation dans le traitement de l'obesite, du diabete de type 2 et des troubles du systeme nerveux central - Google Patents

Nouveaux derives de benzofurane et leur utilisation dans le traitement de l'obesite, du diabete de type 2 et des troubles du systeme nerveux central Download PDF

Info

Publication number
WO2006062481A1
WO2006062481A1 PCT/SE2005/001885 SE2005001885W WO2006062481A1 WO 2006062481 A1 WO2006062481 A1 WO 2006062481A1 SE 2005001885 W SE2005001885 W SE 2005001885W WO 2006062481 A1 WO2006062481 A1 WO 2006062481A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
benzofuran
compound
sulfonate
alkyl
Prior art date
Application number
PCT/SE2005/001885
Other languages
English (en)
Inventor
Graeme Dykes
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0403006A external-priority patent/SE0403006D0/sv
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of WO2006062481A1 publication Critical patent/WO2006062481A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds for the preparation of a medicament against 5-HTg receptor-related disorders.
  • Obesity is a condition characterized by an increase in body fat content resulting in excess body weight above accepted norms. Obesity is the most important nutritional disorder in the western world and represents a major health problem in all industrialized countries. This disorder leads to increased mortality due to increased incidences of diseases such as cardiovascular disease, digestive disease, respiratory disease, cancer and type 2 diabetes. Searching for compounds, which reduce body weight has been going on for many decades.
  • One line of research has been activation of serotoninergic systems, either by direct activation of serotonin receptor subtypes or by inhibiting serotonin reuptake. The exact receptor subtype profile required is however not known.
  • Serotonin (5-hydroxytryptarnine or 5-HT), a key transmitter of the peripheral and central nervous system, modulates a wide range of physiological and pathological functions, including anxiety, sleep regulation, aggression, feeding and depression.
  • Multiple serotonin receptor subtypes have been identified and cloned.
  • the 5-HTg receptor was cloned by several groups in 1993 (Ruat, M. et al. (1993) Biochem. Biophys. Res. Commun.193: 268-276; Sebben, M. et al. (1994) NeuroReport 5: 2553-2557). This receptor is positively coupled to adenylyl cyclase and displays affinity for antidepressants such as clozapine.
  • the compounds according to the present invention show affinity for the 5-HTg receptor as antagonists at nanomolar range.
  • Compounds according to the present invention and their pharmaceutically acceptable salts have 5-HTg receptor antagonist, agonist and partial agonist activity, preferably antagonist activity, and are believed to be of potential use in the treatment or prophylaxis of obesity and type 2 diabetes, to achieve reduction of body weight and/or body weight gain, as well as in the treatment or prophylaxis of disorders of the central nervous system such as anxiety, depression, panic attacks, memory disorders, cognitive disorders, epilepsy, sleep disorders, migraine, anorexia, bulimia, binge eating disorders, obsessive compulsive disorders, psychoses, Alzheimer's disease, Parkinson's disease, Huntington's chorea and/or schizophrenia, panic attacks, Attention Deficit Hyperactive Disorder (ADHD), withdrawal from drug abuse (e.g.
  • ADHD Attention Deficit Hyperactive Disorder
  • body weight disorders refers to the disorders caused by an imbalance between energy intake and energy expenditure, resulting in abnormal (e.g., excessive) body weight. Such body weight disorders include obesity.
  • the present invention provides a compound having the general Formula (I)
  • R 1 and R 2 are selected from Formula (II) or (III) while the other one of R 1 and R 2 is selected from group of Formula (IV)- (XV):
  • R 4 is selected from (a) aryl, (b) heteroaryl,
  • R 1 or R 2 is selected from a group of Formula (II), wherein any aryl and heteroaryl is optionally independently substituted in one or more positions with a substituent selected from
  • R is each independently selected from (a) H,
  • (c) C 3-7 -cycloalkyl, or two R 5 groups together with the nitrogen to which they are attached form a heterocyclic ring e.g. a heterocyclic ring selected from the group consisting of azetidine, pyrrolidine, piperidine, piperazine, morpholine, and thiomorpholine
  • a heterocyclic ring selected from the group consisting of azetidine, pyrrolidine, piperidine, piperazine, morpholine, and thiomorpholine
  • the hydrogen bearing nitrogen of the piperazine ring may be optionally substituted with a group selected from
  • R 7 is each independently selected from (a) Ci- 6 -alkyl (b) aryl, and
  • heteroaryl wherein any heteroaryl or aryl residue is optionally independently substituted with one or more substituents selected from (a) halogen, (b) C M -alkyl,
  • aryl-C 1 - 2 -alkyl provided that R 1 or R 2 is selected from a group of Formula (II), and (e) cinnamyl, wherein any aryl and heteroaryl is optionally independently substituted in one or more positions with a substituent selected from
  • R 2 is selected from piperazinyl, homopiperazinyl, 2,6-dimethylpiperazinyl, 3,5- dimethylpiperazinyl, 2,5-dimethylpiperazinyl, 2-methylpiperazinyl, 3-methylpiperazinyl;
  • R 3 is hydrogen; and R 4 is selected from pyridinyl and phenyl, wherein phenyl is optionally independently substituted in one or more positions with a substituent selected from:
  • R 2 is selected from piperazinyl, homopiperazinyl, 2,6-dimethylpiperazinyl, 3,5- dimethylpiperazinyl, 2,5-dimethylpiperazinyl, 2-methylpiperazinyl, 3-methylpiperazinyl;
  • R 3 is hydrogen
  • R 4 phenyl optionally independently substituted in one or more positions with a substituent selected from:
  • R 2 is selected from piperazinyl, homopiperazinyl, 3-methylpiperazinyl, 4-methyrpiperazin- 1-yl, homopiperazin-1-ylmethyl, 3-methylpiperazin-l-ylmethyl, and piperazin-1-ylmethyl;
  • R 3 is hydrogen; and
  • R 4 is selected from pyridinyl and phenyl, wherein phenyl is optionally independently substituted in one or more positions with a substituent selected from:
  • R 2 is selected from piperazinyl, homopiperazinyl, 3-methylpiperazinyl, 4-methylpi ⁇ erazin- 1 -yl, homopiperazin- 1 -ylmethyl, 3 -methylpiperazin- 1 -ylmethyl, and piperazin- 1 -ylmethyl;
  • R 3 is hydrogen
  • R 4 is selected from pyridinyl and phenyl, wherein phenyl is optionally independently substituted in one or more positions with a substituent selected from: (a) chlorine
  • Most preferred compounds of the generic Formula (I) are: 2-Methoxy-5-methyl ⁇ henyl 7-piperazin-l -yl-1 -benzofuran-5 -sulfonate, 2-Chlorophenyl-7-piperazin- 1 -yl- 1 -benzofuran-5 -sulfonate, 2-(Trifluoromethyl)-phenyl 7-piperazin- 1 -yl- 1 -benzofuran-5 -sulfonate, Pyridin-3-yl 7-piperazin-l-yl-l-benzofuran-5-sulfonate,
  • Another object of the present invention is a process (A) for the preparation of a compound of Formula (I), comprising the following steps:
  • step c) Reacting the product from step c) with corresponding group selected from formula (IV)-(XV); and optionally thereafter forming a pharmaceutically acceptable salt of the compound of Formula (I).
  • Another object of the present invention is a process (A') for the preparation of a compound of Formula (I), comprising the following steps:
  • Another object of the present invention is to provide a further process (B) for the preparation of a compound according to Formula (I), wherein R 1 is selected from Formula (III) and R 2 is selected from Formula (XIII) and (XIV), which process comprises the reaction of a 7-halo substituted benzofuran derivative of Formula (Ha),
  • Hal is selected from chloro, bromo and iodo, preferably iodo, with an appropriate secondary amine, or a protected derivative thereof, in the presence of a palladium catalyst together with an auxilliary ligand and a base, to give, optionally after deprotection, a compound of Formula (I), wherein R 2 is selected from Formula (XIII) and (XIV); and optionally thereafter forming a pharmaceutically acceptable salt of the compound of Formula (I) .
  • Another object of the present invention is to provide a still further process (C) for the preparation of a compound according to Formula (I), wherein R is selected from Formula (III) and R 2 is selected from Formula (XII) and (XV), which process comprises the following steps: aa) reacting a 7-halo substituted benzofuran derivative of Formula (Ha),
  • R 4 is as defined above, and Hal is selected from chloro, bromo and iodo, preferably iodo, with a metal cyanide salt, to give a compound of Formula (Ilia) wherein R 4 is as defined above; bb) reacting the compound of Formula (Ilia) with a reducing agent, to give a compound of Formula (IVa)
  • R is as defined above; cc) reacting the compound of Formula (IVa) with an appropriate secondary amine, or a protected derivative thereof, in the presence of a suitable reducing agent such as NaBH 4 , NaBH 3 CN or sodium triacetoxyborohydride [NaB(OAc) 3 )H], to give, optionally after deprotection, a compound of Formula (I) wherein R 2 is selected from formula (XII) and (XV); and optionally thereafter forming a pharmaceutically acceptable salt of the compound of formula (I).
  • a suitable reducing agent such as NaBH 4 , NaBH 3 CN or sodium triacetoxyborohydride [NaB(OAc) 3 )H
  • Another object of the present invention is to provide a yet further process (D) for the preparation of a compound according to formula (I), wherein R 1 is selected from formula (III) and R is selected from formula (XII) and (XV), which process comprises the following steps: aaa) reacting a 7-halo substituted benzofuran derivative of formula (Ha),
  • R 4 is as defined above, and Hal is selected from chloro, bromo and iodo, preferably iodo, with tributyl(vinyl)stannane in the presence of a palladium complex such as bis(triphenylphosphine)palladium(II) diacetate [Pd(PPh S ) 2 OAc 2 ] as a catalyst, to give a compound of formula (Va) wherein R 4 is as defined above; bbb) reacting the compound of formula (Va) with osmium tetroxide (OsO 4 ) and sodium periodate, to produce the aldehyde derivative of formula (IVa)
  • a palladium complex such as bis(triphenylphosphine)palladium(II) diacetate [Pd(PPh S ) 2 OAc 2 ] as a catalyst
  • R 4 is as defined above; ccc) reacting a compound of formula (IVa) according to Process C, step cc), described above; and optionally thereafter forming a pharmaceutically acceptable salt of the compound of formula (I).
  • the reaction may be carried out in the presence of a base such as an alkali metal hydroxide such as, for example, an aqueous solution of sodium hydroxide, and a phase transfer catalyst such as benzyltrimethylammonium chloride or bromide in a solvent such as dichloromethane.
  • a base such as an alkali metal hydroxide such as, for example, an aqueous solution of sodium hydroxide
  • a phase transfer catalyst such as benzyltrimethylammonium chloride or bromide
  • a solvent such as dichloromethane
  • the palladium-catalyzed amination may be conducted in the presence of a palladium catalyst such as tris(dibenzylideneacetone)dipalladium(0) [Pd 2 dba 3 ] in conjunction with a ligand such as 9,9-dimethyl-4,6-bis(diphenylphosphino)xanthene
  • a palladium catalyst such as tris(dibenzylideneacetone)dipalladium(0) [Pd 2 dba 3 ] in conjunction with a ligand such as 9,9-dimethyl-4,6-bis(diphenylphosphino)xanthene
  • the cyano derivative of formula (Ilia) may be prepared from the corresponding halo derivative, preferably iodo derivative, of formula (Ha) by reaction with a metal cyanide salt such as Zn(CN) 2 in the presence of a palladium-catalyst such as tetrakis(triphenylphosphine)palladium(0) [Pd(PPh 3 ) 4 ] in a solvent such as dimethylformamide (DMF).
  • a metal cyanide salt such as Zn(CN) 2
  • a palladium-catalyst such as tetrakis(triphenylphosphine)palladium(0) [Pd(PPh 3 ) 4 ]
  • DMF dimethylformamide
  • step bb) the reduction of the nitrile group into an aldehyde function may be performed by aqueous formic acid in the presence of platinum(IV) oxide (PtO 2 ). See, for example: Tetrahedron Lett. 2002, 43, 1395-1396. Additionally, the reaction may optionally be carried out in the presence of a solvent such as tetrahydrofuran (THF).
  • a solvent such as tetrahydrofuran (THF).
  • the reaction may be performed using standard methods for reductive amination.
  • the reaction is typically performed in the presence of acetic acid in a solvent such as THF. See, for example: J Org. Chem. 1996. 61, 3849-3862. Additionally, the reaction may optionally be conducted under the influence of microwaves.
  • step aaa the palladium-catalyzed cross-coupling reaction (Stille coupling) may be conducted in a solvent such as toluene or acetonitrile.
  • the reaction may optionally be conducted under the influence of microwaves.
  • step bbb the oxidative cleavage of the alkene into an aldehyde function may be performed by conditions described in Organic Lett. 2004, 6, 3217-3219.
  • the alkene is treated with osmium tetroxide/sodium periodate in a mixture of polar solvents such as dioxane and water in the presence of a base such as 2,6-lutidine.
  • a suitable protecting group such as tert-butoxycarbonyl (t-BOC) may be introduced prior to reaction in order to prevent undesired reactions at such primary or secondary amino nitrogens.
  • An exemplary N-protected amine having more than one reactive nitrogen atom is N-tert- butoxycarbonylpiperazine.
  • the said protecting group may be cleaved off when it is no longer needed to provide the compound according to Formula (I). The reaction conditions of removing the said protecting group depend upon the choice and the characteristics of this group. Thus e.g.
  • tert-butoxycarbonyl may be removed by treatment with a suitable acid.
  • Protecting group methodologies protection and deprotection are known in the art and are described in, for example, T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3 rd Ed., John Wiley & Sons (1999).
  • An obtained compound of Formula (I) may be converted to another compound of
  • Another object of the present invention is a compound as mentioned above for use in therapy, especially for use in the treatment or prophylaxis of a 5-HTg receptor-related disorder, to achieve reduction of body weight and/or body weight gain.
  • Another object of the present invention is a pharmaceutical formulation comprising a compound as mentioned above as active ingredient, in combination with a pharmaceutically acceptable diluent or carrier, especially for use in the treatment or prophylaxis of a 5-HTg receptor-related disorder, to achieve reduction of body weight and/or body weight gain.
  • Another object of the present invention is a method for treating a human or animal subject suffering from a 5-HT6 receptor-related disorder, to achieve reduction of body weight and/or body weight gain.
  • the method can include administering to a subject (e.g., a human or an animal, dog, cat, horse, cow) in need thereof an effective amount of one or more compounds of any of the formulae herein, their salts, or compositions containing the compounds or salts.
  • the methods delineated herein can also include the step of identifying that the subject is in need of treatment of the 5-HTg receptor-related disorder, to achieve reduction of body weight and/or body weight gain. Identifying a subject in need of such treatment can be in the judgment of a subject or a health care professional and can be subjective (e.g., opinion) or objective (e.g., measurable by a test or diagnostic method).
  • Another object of the present invention is a method for the treatment or prophylaxis of a 5- HTg receptor-related disorder, to achieve reduction of body weight and/or body weight gain, which comprises administering to a subject in need of such treatment an effective amount of a compound as mentioned above.
  • Another object of the present invention is a method for modulating 5-HTg receptor activity, which comprises administering to a subject in need of such treatment an effective amount of a compound as mentioned above.
  • Another object of the present invention is the use of a compound as mentioned above for the manufacture of a medicament for use in the prophylaxis or treatment of a 5- HTg receptor-related disorder, to achieve reduction of body weight and/or body weight gain.
  • the compounds as mentioned above may be agonists, partial agonists or antagonists for the 5-HTg receptor.
  • the compounds act as partial agonists or antagonists for the 5-HTg receptor. More preferably the compounds act as antagonists for the 5-HTg receptor.
  • 5-HTg receptor-related disorders are obesity; type II diabetes; disorders of the central nervous system such as anxiety, depression, panic attacks, memory disorders, cognitive disorders, epilepsy, sleep disorders, migraine, anorexia, bulimia, binge eating disorders, obsessive compulsive disorders, psychoses, Alzheimer's disease, Parkinson's disease, Huntington's chorea, schizophrenia, attention deficit hyperactive disorder (ADHD), withdrawal from drug abuse (e.g. abuse of amphetamine, ***e abuse and/or nicotine), neurodegenerative diseases characterized by impaired neuronal growth, and pain.
  • the compounds and compositions are useful for treating diseases, to achieve reduction of body weight and/or body weight gain.
  • the diseases include obesity; type II diabetes; disorders of the central nervous system such as anxiety, depression, panic attacks, memory disorders, cognitive disorders, epilepsy, sleep disorders, migraine, anorexia, bulimia, binge eating disorders, obsessive compulsive disorders, psychoses, Alzheimer's disease, Parkinson's disease, Huntington's chorea, schizophrenia, attention deficit hyperactive disorder (ADHD), withdrawal from drug abuse (e.g. abuse of amphetamine, ***e abuse and/or nicotine), neurodegenerative diseases characterized by impaired neuronal growth, / and pain.
  • ADHD attention deficit hyperactive disorder
  • the invention relates to a method for treating or preventing an aforementioned disease comprising administering to a subject in need of such treatment an effective amount or composition delineated herein.
  • Another object of the present invention is a cosmetic composition
  • a cosmetic composition comprising a compound as mentioned above as active ingredient, in combination with a cosmetically acceptable diluent or carrier, especially for use in the prophylaxis or treatment of a 5-HTg receptor- related disorder, to achieve reduction of body weight and/or body weight gain.
  • C 1-6 -alkyl denotes a straight or branched alkyl group having from 1 to 6 carbon atoms.
  • Examples of said C 1-6 -alkyl include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl and straight- and branched-chain pentyl and hexyl.
  • Ci- ⁇ -alkyl all subgroups thereof are contemplated such as C 1-5 -alkyl, C 1-4 -alkyl, Ci- 3 -alkyl, C ⁇ -alkyl, C 2-6 -alkyl, C 2-5 -alkyl, C 2-4 -alkyl, C 2-3 -alkyl, C 3-6 -alkyl, C 4-5 -alkyl, etc.
  • aryl-C 1-6 -alkyl means a C h alky! group substituted by one or more aryl groups.
  • hydroxy-C 1-4 -alkyl denotes a straight or branched alkyl group that has a hydrogen atom thereof replaced with OH.
  • examples of said hydroxy-C 1-4 -alkyl include hydroxymethyl, 2-hydroxyethyl, 2- hydroxypropyl and 2-hydroxy-2-methylpropyl.
  • C 1-6 -alkoxy denotes a straight or branched alkoxy group having from 1 to 6 carbon atoms.
  • Examples of said C 1-6 - alkoxy include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, t- butoxy and straight- and branched-chain pentoxy and hexoxy.
  • C 1-6 - alkoxy For parts of the range "C 1-6 - alkoxy" all subgroups thereof are contemplated such as C 1-5 -alkoxy, C 1-4 -alkoxy, C 1-3 - alkoxy, C 1-2 -alkoxy, C 2-6 -alkoxy, C 2-5 -alkoxy, C 2-4 -alkoxy, C 2-3 -alkoxy, C 3-6 -alkoxy, C 4-5 - alkoxy, etc.
  • the term "C 1-4 -alkoxy-C 2-4 -alkyl” denotes a straight or branched alkoxy group having from 1 to 4 carbon atoms connected to an alkyl group having from 1 to 4 carbon atoms. Examples of said C 1-4 -alkoxy-C 2-4 -alkyl include methoxymethyl, ethoxymethyl, iso-propoxymethyl, n-butoxymethyl, and t-butoxymethyl.
  • C 1-4 -alkoxy-C 2-4 -alkyl For parts of the range "C 1-4 -alkoxy-C 2-4 -alkyl" all subgroups thereof are contemplated such as C 1 - 3 -alkoxy-C 2-4 -alkyl, C 1-4 -alkoxy-C 2-3 -alkyl, C 1-2 -alkoxy-C 2 - 3 -alkyl, C 2-4 -alkoxy-C 2-4 - alkyl, C 2-3 -alkoxy-C 2-4 -alkyl, C 2-4 -alkoxy-C 2-3 -alkyl, etc.
  • C 2 _ 6 -alkenyl denotes a straight or branched alkenyl group having from 2 to 6 carbon atoms.
  • Examples of said C 2-6 -alkenyl include vinyl, allyl, 2,3-dimethylallyl, 1-butenyl, 1-pentenyl, and 1-hexenyl.
  • C 2-6 -alkenyl all subgroups thereof are contemplated such as C2 -5 -alkenyl, C 2-4 - alkenyl, C 2-3 -alkenyl, C 3-6 -alkenyl, C 4-5 -alkenyl, etc.
  • aryl-C 2 . 6 -alkenyl means a
  • C 2-6 -alkenyl group substituted by one or more aryl groups examples include styryl and cinnamyl.
  • C 2 - 4 -alkynyl denotes a straight or branched alkynyl group having from 2 to 4 carbon atoms.
  • Examples of said C2 -4 -alkynyl include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, and 2-butynyl.
  • C 3-7 -cycloalkyl denotes a cyclic alkyl group having a ring size from 3 to 7 carbon atoms.
  • examples of said cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methylcyclohexyl, and cycloheptyl.
  • C 3-7 -cycloalkyl all subgroups thereof are contemplated such as C 3-6 -cycloalkyl, C 3-5 -cycloalkyl, C 3-4 -cycloalkyl, C 4-7 -cycloalkyl, C 4-
  • aryl refers to a hydrocarbon ring system of one, two or three rings, having at least one aromatic ring, ,and having from 6 to 14 ring carbon atoms.
  • aryl groups include: phenyl, pentalenyl, indenyl, indanyl, 1,2,3,4-tetrahydronaphthyl, 1-naphthyl, 2-naphthyl, fiuorenyl, anthryl, phenanthryl and pyrenyl.
  • An aryl group can be linked to the remainder of the molecule through any available carbon atom in the aryl group whether present in an aromatic ring or a partially saturated ring.
  • aryl rings may be optionally substituted.
  • aryloxy refers to an aryl group bonded to an oxygen atom.
  • heteroaryl refers to a mono- or bicyclic aromatic ring system, only one ring need be aromatic, and the said heteroaryl moiety can be linked to the remainder of the molecule via a carbon or nitrogen atom in any ring, and having from 5 to 10 ring atoms (mono- or bicyclic), in which one or more of the ring atoms are other than carbon, such as nitrogen, sulphur, oxygen and selenium.
  • heteroaryl rings examples include furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, thiazolyl, isothiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, chromanyl, quinazolinyl, indolyl, isoindolyl, indolinyl, isoindolinyl, indazolyl, pyrazolyl, pyridazinyl, quinolinyl, isoquinolinyl, benzofuranyl, dihydrobenzofuranyl, benzodioxolyl, benzodioxinyl, benzothienyl, benzimidazolyl, benzothiazolyl, benzothiadiazolyl, and benzotriazolyl groups. If a bicyclic heteroaryl ring is substituted, it may be substituted in any ring.
  • heterocyclic refers to a non- aromatic (i.e., partially or fully saturated) mono- or bicyclic ring system having 4 to 10 ring atoms with at least one heteroatom such as O, N, or S, and the remaining ring atoms are carbon.
  • heterocyclic groups include piperidyl, tetrahydropyranyl, tetrahydrofuranyl, azepinyl, azetidinyl, pyrrolidinyl, morpholinyl, imidazolinyl, thiomorpholinyl, pyranyl, dioxanyl, and piperazinyl groups.
  • halogen shall mean fluorine, chlorine, bromine or iodine.
  • “Pharmaceutically acceptable” means being useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes being useful for veterinary use as well as human pharmaceutical use.
  • Treatment includes prophylaxis of the named disorder or condition, or amelioration or elimination of the disorder once it has been established, "An effective amount” refers to an amount of a compound that confers a therapeutic effect on the treated subject.
  • the therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect).
  • prodrug forms means a pharmacologically acceptable derivative, such as an ester or an amide, which derivative is biotransformed in the body to form the active drug.
  • pharmacologically acceptable derivative such as an ester or an amide
  • the following abbreviations have been used:
  • DMSO dimethyl sulphoxide
  • EDTA means ethylenediamine tetraacetic acid
  • EGTA ethylenebis(oxyethylenenitrilo)tetraacetic acid
  • HEPES 4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid
  • HPLC means high performance liquid chromatography
  • LSD means lysergic acid, diethylamide
  • MeCN means acetonitrile
  • SPA Scintillation Proximity Assay
  • THF tetrahydrofuran
  • ABS in Table 1 means absolute configuration
  • MeOH means methanol
  • p-ether means petroleum ether (40-60 0 C)
  • RT retention time
  • rt or r.t room temperature
  • t-BOC t-butoxycarbonyl
  • DCM dichloromethane
  • TFA trifluoroacetic acid. All isomeric forms possible (pure enantiomers, diastereomers, tautomers, racemic mixtures and unequal mixtures of two enantiomers) for the compounds delineated are within the scope of the invention. Such compounds can also occur as cis- or trans-, E- or Z- double bond isomer forms. AU isomeric forms are contemplated.
  • the compounds of the Formula (I) may be used as such or, where appropriate, as pharmacologically acceptable salts (acid or base addition salts) thereof.
  • pharmacologically acceptable addition salts mentioned above are meant to comprise the therapeutically active non-toxic acid and base addition salt forms that the compounds are able to form.
  • Compounds that have basic properties can be converted to their pharmaceutically acceptable acid addition salts by treating the base form with an appropriate acid.
  • Exemplary acids include inorganic acids, such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulphuric acid, phosphoric acid; and organic acids such as formic acid, acetic acid, propanoic acid, hydroxyacetic acid, lactic acid, pyruvic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, benzenesulphonic acid, toluenesulphonic acid, methanesulphonic acid, trifluoroacetic acid, fumaric acid, succinic acid, malic acid, tartaric acid, citric acid, salicylic acid, p-aminosalicylic acid, pamoic acid, benzoic acid, ascorbic acid and the like.
  • organic acids such as formic acid, acetic acid, propanoic acid, hydroxyacetic acid, lactic acid, pyruvic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, benzenesulphonic acid, toluen
  • Exemplary base addition salt forms are the sodium, potassium, calcium salts, and salts with pharmaceutically acceptable amines such as, for example, ammonia, alkylamines, benzathine, and amino acids, such as, e.g. arginine and lysine.
  • the term addition salt as used herein also comprises solvates which the compounds and salts thereof are able to form, such as, for example, hydrates, alcoholates and the like.
  • the compounds of the invention are formulated into pharmaceutical formulations for oral, rectal, parenteral or other mode of administration.
  • Pharmaceutical formulations are usually prepared by mixing the active substance, or a pharmaceutically acceptable salt thereof, with conventional pharmaceutical excipients.
  • excipients are water, gelatin, gum arabicum, lactose, microcrystalline cellulose, starch, sodium starch glycolate, calcium hydrogen phosphate, magnesium stearate, talcum, colloidal silicon dioxide, and the like.
  • Such formulations may also contain other pharmacologically active agents, and conventional additives, such as stabilizers, wetting agents, emulsifiers, flavouring agents, buffers, and the like.
  • the amount of active compounds is between 0.1-95% by weight of the preparation, preferably between 0.2-20% by weight in preparations for parenteral use and more preferably between 1-50% by weight in preparations for oral administration.
  • the formulations can be further prepared by known methods such as granulation, compression, microencapsulation, spray coating, etc.
  • the formulations may be prepared by conventional methods in the dosage form of tablets, capsules, granules, powders, syrups, suspensions, suppositories or injections.
  • Liquid formulations may be prepared by dissolving or suspending the active substance in water or other suitable vehicles. Tablets and granules may be coated in a conventional manner.
  • the invention relates to methods of making compounds of any of the formulae herein comprising reacting any one or more of the compounds of the formulae delineated herein, including any processes delineated herein.
  • the compounds of the Formula (I) above may be prepared by, or in analogy with, conventional methods. The processes described above may be carried out to give a compound of the invention in the form of a free base or as an acid addition salt.
  • a pharmaceutically acceptable acid addition salt may be obtained by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Examples of addition salt forming acids are mentioned above.
  • the compounds of Formula (I) may possess one or more chiral carbon atoms, and they may therefore be obtained in the form of optical isomers, e.g. as a pure enantiomer, or as a mixture of enantiomers (racemate) or as a mixture containing diastereomers.
  • optical isomers e.g. as a pure enantiomer, or as a mixture of enantiomers (racemate) or as a mixture containing diastereomers.
  • the separation of mixtures of optical isomers to obtain pure enantiomers is well known in the art and may, for example, be achieved by fractional crystallization of salts with optically active (chiral) acids or by chromatographic separation on chiral columns.
  • the chemicals used in the synthetic routes delineated herein may include, for example, solvents, reagents, catalysts, and protecting group and deprotecting group reagents.
  • the methods described above may also additionally include steps, either before or after the steps described specifically herein, to add or remove suitable protecting groups in order to ultimately allow synthesis of the compounds.
  • various synthetic steps may be performed in an alternate sequence or order to give the desired compounds.
  • Synthetic chemistry transformations useful in synthesizing applicable compounds are known in the art and include, for example, those described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L.
  • the necessary starting materials for preparing the compounds of Formula (I) are either known or may be prepared in analogy with the preparation of known compounds.
  • the dose level and frequency of dosage of the specific compound will vary depending on a variety of factors including the potency of the specific compound employed, the metabolic stability and length of action of that compound, the patient's age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the condition to be treated, and the patient undergoing therapy.
  • the daily dosage may, for example, range from about 0.001 mg to about 100 mg per kilo of body weight, administered singly or multiply in doses, e.g. from about 0.01 mg to about 25 mg each. Normally, such a dosage is given orally but parenteral administration may also be chosen.
  • Preparative HPLC/MS was performed on a Waters/Micromass Platform ZQ system equipped with System A: ACE 5 C8 column (19x50mm), eluents: MiIIiQ water, MeCN and MilliQ/MeCN/0.1%TFA and system B: Xterra MS Cl 8, 5 ⁇ m column (19x50mm), eluents: MiIIiQ water, MeCN and NH 4 HCO 3 (10OmM).
  • Analytical HPLC was carried out on an Agilent Series 1100 system using either an ACE 3 C8 (3 ⁇ m, 3.0x50 mm) column (System A), a Chromolith SpeedROD RP-18e (4.6x50 mm) column (System B), or a YMC ODS-AQ (3 ⁇ m, 3.0x33 mm) column (System C).
  • Acetonitrile and water containing 0.1% TFA were used as mobile phase for both analytical and preparative HPLC.
  • Preparative flash chromatography was performed on Merck silica gel 60 (230-400 mesh). Microwave reactions were performed with a Personal Chemistry Smith Creator using 0.5-2 mL or 2-5 mL Smith Process Vials fitted with aluminum caps and septa. The compounds were named using ACD Name 6.0.
  • the first synthetic step was performed according to the method described in the literature (J.Med.Chem. (2002), 45(5): 1086-1097).
  • 7-Iodo-l -benzofuran-5-sulfonyl chloride (0.095 g, 0.28 mmol; Intermediate 3) was dissolved in dichloromethane (5 mL) and then treated with 5-methyl-2-methoxyphenol (0.040 g, 0.29 mmol in 5 mL DCM), aqueous sodium_ hydroxide (5.0 M, 3 mL, 15 mmol) and benzyltrimethylammonium chloride (0.001 g, 0.01 mmol). The mixture was rapidly stirred at 40 °C.
  • the sample (0.087 g, 0.195 mmol) was dissolved in xylene (1.5 mL) at room temperature was treated with sodium tert-butoxide (0.029 g, 0.234 mmol), Xantphos (0.003 g, 0.005 mmol), tris(dibenzylideneacetone)dipalladium(0.004 g, 0.005 mmol) and t-BOC-piperazine (0.036 g, 0.195 mmol).
  • the resulting suspension was heated to 100 0 C for 16h. On cooling, the mixture was filtered through celite eluting with xylene. The filtrate was concentrated under reduced pressure to give 110 mg of a brown oil.
  • reaction mixture was diluted with (50 mL) EtOAc and washed with IM HCl (25 mL), followed by water (25 ml) and brine (25 mL), dried Na 2 SO 4 and evaporated to give 818.8 mg.
  • the ability of a compound according to the invention to bind to a 5-HT 6 receptor, and to be pharmaceutically useful, can be determined using in vivo and in vitro assays known in the art.
  • Binding affinity experiment for the jtiurnani 5-HT6 receptor are performed in HEK293 cells transfected with 5-HT 6 receptor using ( 3 H)-LSD as labeled ligand according to the general method as described by Boess F.G et al. Neuropharmacology vol. 36(4/5) 713-720, 1997.
  • the HEK-293 cell line transfected with the human 5-HT 6 receptor was cultured in Dulbeccos Modified Eagles Medium containing 5 % dialyzed foetal bovine serum, (Gibco BRL 10106-169), 0.5 niM sodium pyruvate and 400 ⁇ g/ml Geneticin (G-418) (Gibco BRL 10131-019). The cells were passaged 1:10, twice a week.
  • Disposable Compounds were diluted in Costar 96 well V-bottom polypropylene plates (Corning Inc. Costar, NY, USA). Samples were incubated in Packard Optiplate (Packard Instruments B.V., Groningen, The Netherlands). The total amount of added radioligand was measured in Packard 24- well Barex plates (Packard Instruments B. V., Groningen, The Netherlands) in the presence of MicroscintTM 20 scintillation fluid (Packard Bioscience, Meriden, CT, USA).
  • the binding buffer consisted of 20 mM HEPES, 150 mM NaCl 5 10 mM MgCl 2, and 1 niM, EDTA, pH 7.4.
  • Cells were grown to approximately 90% confluence on 24.5 x 24.5 NUNC culture dishes.
  • the medium was aspirated, and after rinsing with ice-cold PBS, the cells were scraped off using 25 ml Tris buffer (50 mM Tris-HCl, 1 mM EDTA, 1 mM EGTA, pH 7.4) and a window scraper.
  • the cells were then broken with a Polytron homogeniser, and remaining particulate matter was removed by low-speed centrifugation, 100Ox g for 5 min. Finally, the membranes were collected by high-speed centrifugation (20 00Ox g), suspended in binding buffer, and frozen in aliquots at -70°C.
  • Frozen cell membranes were thawed, immediately rehomogenized with a Polytron homogenizer, and coupled to SPA wheat germ agglutinin beads (Amersham Life Sciences, Cambridge, England) for 30 min under continuous shaking of the tubes. After coupling, the beads were centrifuged for 10 minutes at 1000 g, and subsequently suspended in 20 ml of binding buffer per 96-well plate The binding reaction was then initiated by adding radioligand and test compounds to the bead-membrane suspension. Following incubation at room temperature, the assay plates were subjected to scintillation counting.
  • the K d value was estimated to 2.6 ⁇ 0.2 nM based on four separate experiments.
  • 5-HT caused a concentration dependent inhibition of [ 3 H] LSD binding with an over all average Ki value of 236 nM when tested against two different membrane preparations.
  • the inter assay variability over three experiments showed a CV of 10% with an average Kj values of 173 nM (SD 30) and a Hill coefficient of 0.94 (SD 0.09).
  • Protein concentrations were determined with BioRad Protein Assay (Bradford, M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976;72:248-54). Bovine serum albumin was used as standard.
  • the radioactivity was determined in a Packard TopCountTM scintillation counter (Packard Instruments, Meriden, CT, USA) at a counting efficiency of approximately 20 %. The counting efficiency was determined in separate sets of experiments.
  • Antagonists to the human 5-HT 6 receptor were characterized by measuring inhibition of 5- HT induced increase in cAMP in HEK 293 cells expressing the human 5-HT 6 receptor (see Boess et al. (1997) Neuropharmacology 36: 713-720). Briefly, HEK293/5-HT 6 cells were seeded in polylysine coated 96-well plates at a density of 25,000 / well and grown in DMEM (Dulbecco's Modified Eagle Medium) (without phenol-red) containing 5% dialyzed Foetal Bovine Serum for 48 h at 37°C in a 5% CO 2 incubator.
  • DMEM Dynamic Eagle Medium
  • the medium was then aspirated and replaced by 0.1 ml assay medium (Hanks Balance Salt Solution containing 20 mM HEPES, 1.5 mM isobutylmethylxanthine and 1 mg/ml bovine serum albumin). After addition of test substances, 50 ⁇ l dissolved in assay medium, the cells were incubated for 10 min at 37°C in a 5% CO 2 incubator. The medium was again aspirated and the cAMP content was determined using a radioactive cAMP kit (Amersham Pharmacia Biotech, BIOTRAK RPA559).
  • the compounds in accordance with the invention have a selective affinity to human 5-HTg receptors with Kj and ICso.corr values between 0.5 nM and 5 ⁇ M and are antagonists, agonists or partial agonists at the human 5-HTg receptor.
  • the compounds show good selectivity over the human 5-HT la , 5-HT 2a , 5-HT 2b and 5 -HT 2c receptors.
  • Obese (ob/ob) mouse is selected as the primary animal model for screening as this mutant mouse consumes high amounts of food resulting in a high signal to noise ratio.
  • the effect of the compounds on food consumption is also studied in wild type (C57BL/6J) mice. The amount of food consumed during 15 hours of infusion of compounds is recorded.
  • mice Male mice (obese C57BL/6JBom-Lep ob and lean wild-type C57Bl/6JBom; Bomholtsgaard, Denmark) 8-9 weeks with an average body weight of 50 g (obese) and 25 g (lean) are used in all the studies.
  • the animals are housed singly in cages at 23 ⁇ 1°C, 40- 60 % humidity and have free access to water and standard laboratory chow.
  • the 12/12-h light/dark cycle is set to lights off at 5 p.m.
  • the animals are conditioned for at least one week before start of study.
  • test compounds are dissolved in solvents suitable for each specific compound such as cyclodextrin, cyclodextrin/methane sulfonic acid, polyethylene glycol/methane sulfonic acid, saline. Fresh solutions are made for each study. Doses of 30, 50 and 100 mg kg ⁇ day "1 are used. The purity of the test compounds is of analytical grade.
  • the animals are weighed at the start of the study and randomized based on body weight.
  • Alzet osmotic minipumps (Model 2001D; infusion rate 8 ⁇ l/h) are used and loaded essentially as recommended by the Alzet technical information manual (Alza Scientific
  • the minipumps are either filled with different concentrations of test compounds dissolved in vehicle or with only vehicle solution and maintained in vehicle pre-warmed to 37°C (approx. Ih).
  • the minipumps are implanted subcutaneously in the neck/back region under short acting anesthesia (metofane/enflurane). This surgical procedure lasts approximately 5 min. It takes about 3 h to reach steady state delivery of the compound.
  • the weight of the food pellets are measured at 5 p.m. and at 8 p. m. for two days before
  • the plasma sample proteins are precipitated with methanol, centrifuged and the supernatant is transferred to HPLC vials and injected into the liquid chromatography /mass spectrometric system.
  • the mass spectrometer is set for electrospray positive ion mode and
  • Food consumption for 15 hours is measured for the three consecutive days and the percentage of basal level values is derived for each animal from the day before and after treatment. The values are expressed as mean ⁇ SD and ⁇ SEM from eight animals per dose group. Statistical evaluation is performed by Kruskal-Wallis one-way ANOVA using the percent basal values. If statistical significance is reached at the level of p ⁇ 0.05, Mann- Whitney U-test for statistical comparison between control and treatment groups is performed.
  • the compounds according to the invention show an effect in the range of 50-200 mg/kg.

Abstract

L'invention concerne des composés de formule générale (I), dans laquelle R1, R2 et R3 sont tels que définis dans la description; des compositions pharmaceutiques contenant ces composés; ainsi que l'utilisation de ces composés dans la prophylaxie et le traitement d'états pathologiques liés à l'obésité, au diabète de type 2 et/ou aux troubles du SNC.
PCT/SE2005/001885 2004-12-09 2005-12-09 Nouveaux derives de benzofurane et leur utilisation dans le traitement de l'obesite, du diabete de type 2 et des troubles du systeme nerveux central WO2006062481A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0403006A SE0403006D0 (sv) 2004-12-09 2004-12-09 New compounds
SE0403006-0 2004-12-09
US66626105P 2005-03-28 2005-03-28
US60/666,261 2005-03-28

Publications (1)

Publication Number Publication Date
WO2006062481A1 true WO2006062481A1 (fr) 2006-06-15

Family

ID=36578194

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2005/001885 WO2006062481A1 (fr) 2004-12-09 2005-12-09 Nouveaux derives de benzofurane et leur utilisation dans le traitement de l'obesite, du diabete de type 2 et des troubles du systeme nerveux central

Country Status (1)

Country Link
WO (1) WO2006062481A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102060810A (zh) * 2010-12-20 2011-05-18 金坛市爱特生物科技有限公司 一种n-叔丁氧羰基-哌嗪的提纯方法
US8367676B2 (en) 2009-06-30 2013-02-05 Astrazeneca Ab 2-carboxamide-7-piperazinyl-benzofuran derivatives 774
US8507469B2 (en) 2007-03-23 2013-08-13 Abbott Gmbh & Co. Kg Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
US9012457B2 (en) 2010-12-20 2015-04-21 Astrazeneca Ab 2-carboxamide-4-piperazinyl-benzofuran derivative
CN109879840A (zh) * 2019-03-12 2019-06-14 沈阳大学 4-哌嗪甲基-7-羟基苯并呋喃类化合物及其医药用途

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021619A1 (fr) * 1993-03-16 1994-09-29 Pfizer Inc. Derives de naphtalene
WO1995000478A1 (fr) * 1993-06-18 1995-01-05 Lundbeck & Co As H Aryltriflates et composes connexes
WO1995011243A1 (fr) * 1993-10-19 1995-04-27 Smithkline Beecham Plc Derives de benzanilide en tant qu'antagonistes du recepteur de 5ht-1d
WO1998027081A1 (fr) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Derives de sulfamide, procede de preparation de ces derives et utilisation de ces derniers en tant que medicaments
WO2001032646A2 (fr) * 1999-11-05 2001-05-10 Smithkline Beecham P.L.C. Nouveaux composes
WO2002098857A1 (fr) * 2001-06-07 2002-12-12 F. Hoffmann-La Roche Ag Nouveaux derives de l'indole a affinite pour le recepteur 5-ht6
WO2002100822A1 (fr) * 2001-06-11 2002-12-19 Biovitrum Ab Composants de sulfonamide substitues, procede d'utilisation de ceux-ci comme medicaments dans le traitement de troubles cns, de l'obesite et du diabete de type ii
WO2003014097A1 (fr) * 2001-08-10 2003-02-20 F. Hoffmann-La Roche Ag Derives d'arylsulfonyle avec affinite pour le recepteur 5-ht¿6?
WO2003013510A1 (fr) * 2001-08-07 2003-02-20 Smithkline Beecham P.L.C. 3-arylsulfonyl-7-piperazinyl- indols, -benzofurans et benzothiophenes a affinite avec les recepteurs 5-ht6 pour le traitement de troubles du snc
WO2003068752A1 (fr) * 2002-02-13 2003-08-21 Glaxo Group Limited Derives benzenesulfonamide utilises comme antipsychotiques
WO2004000828A1 (fr) * 2002-06-20 2003-12-31 Biovitrum Ab Composes utiles pour le traitement de l'obesite, du diabete de type ii et des troubles du systeme nerveux central
WO2004026830A1 (fr) * 2002-09-17 2004-04-01 F. Hoffmann-La Roche Ag Indoles substitues en 2,7 et leur utilisation en tant que modulateurs 5-ht6
WO2004074286A1 (fr) * 2003-02-14 2004-09-02 Wyeth Derives de heterocyclyl-3-sulfonylazaindole ou -azaindazole utilises comme ligands de la 5-hydroxytryptamine-6
WO2005021530A1 (fr) * 2003-08-29 2005-03-10 Glaxo Group Limited Derives de 8- (1-piperazinyl)- quinoleine et leur utilisation pour le traitement de troubles du systeme nerveux central
WO2005026125A1 (fr) * 2003-09-12 2005-03-24 Glaxo Group Limited Composes de quinoleine et compositions pharmaceutiques contenant ceux-ci
WO2005058858A1 (fr) * 2003-12-19 2005-06-30 Biovitrum Ab Nouveaux derives de benzofurane, pouvant etre utilises dans la prophylaxie ou le traitement des affections associees au recepteur de 5-ht6

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021619A1 (fr) * 1993-03-16 1994-09-29 Pfizer Inc. Derives de naphtalene
WO1995000478A1 (fr) * 1993-06-18 1995-01-05 Lundbeck & Co As H Aryltriflates et composes connexes
WO1995011243A1 (fr) * 1993-10-19 1995-04-27 Smithkline Beecham Plc Derives de benzanilide en tant qu'antagonistes du recepteur de 5ht-1d
WO1998027081A1 (fr) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Derives de sulfamide, procede de preparation de ces derives et utilisation de ces derniers en tant que medicaments
WO2001032646A2 (fr) * 1999-11-05 2001-05-10 Smithkline Beecham P.L.C. Nouveaux composes
WO2002098857A1 (fr) * 2001-06-07 2002-12-12 F. Hoffmann-La Roche Ag Nouveaux derives de l'indole a affinite pour le recepteur 5-ht6
US20030073700A1 (en) * 2001-06-07 2003-04-17 Beard Colin Charles New indole derivatives with 5HT6 receptor affinity
WO2002100822A1 (fr) * 2001-06-11 2002-12-19 Biovitrum Ab Composants de sulfonamide substitues, procede d'utilisation de ceux-ci comme medicaments dans le traitement de troubles cns, de l'obesite et du diabete de type ii
WO2003013510A1 (fr) * 2001-08-07 2003-02-20 Smithkline Beecham P.L.C. 3-arylsulfonyl-7-piperazinyl- indols, -benzofurans et benzothiophenes a affinite avec les recepteurs 5-ht6 pour le traitement de troubles du snc
WO2003014097A1 (fr) * 2001-08-10 2003-02-20 F. Hoffmann-La Roche Ag Derives d'arylsulfonyle avec affinite pour le recepteur 5-ht¿6?
WO2003068752A1 (fr) * 2002-02-13 2003-08-21 Glaxo Group Limited Derives benzenesulfonamide utilises comme antipsychotiques
WO2004000828A1 (fr) * 2002-06-20 2003-12-31 Biovitrum Ab Composes utiles pour le traitement de l'obesite, du diabete de type ii et des troubles du systeme nerveux central
WO2004026830A1 (fr) * 2002-09-17 2004-04-01 F. Hoffmann-La Roche Ag Indoles substitues en 2,7 et leur utilisation en tant que modulateurs 5-ht6
WO2004074286A1 (fr) * 2003-02-14 2004-09-02 Wyeth Derives de heterocyclyl-3-sulfonylazaindole ou -azaindazole utilises comme ligands de la 5-hydroxytryptamine-6
WO2005021530A1 (fr) * 2003-08-29 2005-03-10 Glaxo Group Limited Derives de 8- (1-piperazinyl)- quinoleine et leur utilisation pour le traitement de troubles du systeme nerveux central
WO2005026125A1 (fr) * 2003-09-12 2005-03-24 Glaxo Group Limited Composes de quinoleine et compositions pharmaceutiques contenant ceux-ci
WO2005058858A1 (fr) * 2003-12-19 2005-06-30 Biovitrum Ab Nouveaux derives de benzofurane, pouvant etre utilises dans la prophylaxie ou le traitement des affections associees au recepteur de 5-ht6

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8507469B2 (en) 2007-03-23 2013-08-13 Abbott Gmbh & Co. Kg Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
US8367676B2 (en) 2009-06-30 2013-02-05 Astrazeneca Ab 2-carboxamide-7-piperazinyl-benzofuran derivatives 774
US8859534B2 (en) 2009-06-30 2014-10-14 Acturum Life Science AB 2-carboxamide-7-piperazinyl-benzofuran derivatives
CN102060810A (zh) * 2010-12-20 2011-05-18 金坛市爱特生物科技有限公司 一种n-叔丁氧羰基-哌嗪的提纯方法
US9012457B2 (en) 2010-12-20 2015-04-21 Astrazeneca Ab 2-carboxamide-4-piperazinyl-benzofuran derivative
CN109879840A (zh) * 2019-03-12 2019-06-14 沈阳大学 4-哌嗪甲基-7-羟基苯并呋喃类化合物及其医药用途
CN109879840B (zh) * 2019-03-12 2023-04-11 沈阳大学 4-哌嗪甲基-7-羟基苯并呋喃类化合物及其医药用途

Similar Documents

Publication Publication Date Title
US20060142269A1 (en) New compounds
RU2449990C2 (ru) Индолы в качестве модуляторов 5-ht6
US20060148818A1 (en) Novel tetraydrospiro(piperdine-2,7'- pyrrolo{3,2-b}pyridine derivatives and novel in-dole derivatives useful in the treatment of 5-ht6 receptor-related disorders
KR100888906B1 (ko) 치환 술폰아미드 화합물, ｃｎｓ 장애, 비만 및 ⅱ 형당뇨병 치료용 약제로서의 이들의 사용 방법
US20110015185A1 (en) Benzofuran Compounds
EP1694663A1 (fr) Nouveaux derives de benzofurane, pouvant etre utilises dans la prophylaxie ou le traitement des affections associees au recepteur de 5-ht6
WO2006062481A1 (fr) Nouveaux derives de benzofurane et leur utilisation dans le traitement de l'obesite, du diabete de type 2 et des troubles du systeme nerveux central
JP2010520917A (ja) 肥満治療用三環式イソキノリン誘導体
AU2006259082B2 (en) Benzofuranyl derivatives as 5-HT6-receptor inhibitors
US7960374B2 (en) Tricyclic compounds, compositions, and methods useful in the treatment or prophylaxis of 5-HT6 receptor-related disorders
ZA200602756B (en) Novel tetraydrospiro{piperidine-2,7'-pyrrolo[3,2-b]pyridine derivatives and novel indole derivatives useful in the treatment of 5-HT6 receptor-related disorders
EP1897876A2 (fr) Composés utiles pour le traitement de l'obésité, du diabète de type II et des troubles du système nerveux central
KR20070020373A (ko) 5-ＨＴ6 수용체-관련 장애의 치료에 유용한 신규한 테트라히드로스피로｛피페리딘-2,7'-피롤로[3,2-ｂ]피리딘｝ 유도체 및 신규한 인돌 유도체
NZ577103A (en) 8-Sulfonyl-1,3,4,8-tetrahydro-2H-[1,4]oxazepino[6,7-e]indole derivatives and their use as 5-HT6 receptor ligands
MXPA06006974A (en) Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05815775

Country of ref document: EP

Kind code of ref document: A1